Arkion Life Sciences announces the promotion of two executives in its EgCel® IgY Technology business unit. Both are key executives within the business unit and will drive adoption and growth of the EgCel portfolio of products (EggTek® and ActivEgg®), pipeline innovations and new services brought to market.

Shawn W. Jones, PhD, has been promoted to Director of Innovation & Manufacturing, EgCel IgY Technology. Jones is a published researcher and microbiologist who oversees production, research and development on the EgCel line of immune support products. He joined Arkion in 2020 and was most recently the Process and Development Manager. Prior to coming to Arkion, he worked to develop and scale-up novel fermentation and microbial processes for biomaterials and nutrition products.

Michelle Tollefson has been promoted to Director of Commercialization, EgCel IgY Technology. Former Business Director for EgCel IgY, Tollefsonjoined Arkion in 2021. In her new role, she will bring new products and services to market and ensure their commercial success. Prior to Arkion, she held senior brand and marketing roles at Elanco, Bayer Animal Health, Boehringer Ingelheim, and Pfizer, with a track record of delivering growth across dairy, swine, poultry, and pet health segments.

EgCel IgY products provide a blanket of specific IgY antibodies to help close “the gap” between passive immunity provided by colostrum and the animal’s active immunity provided by vaccines.